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Cutting Edge: NKG2D Signaling Enhances NK Cell
Responses but Alone Is Insufficient To Drive Expansion
during Mouse Cytomegalovirus Infection
Tsukasa Nabekura,*,†,‡,1 Dagmar Gotthardt,*,†,1 Kouta Niizuma,*,x
Tihana Trsan ,{ Tina Jenus ,{ Stipan Jonjic ,{ and Lewis L. Lanier *,†
NK cells play a critical role in host defense against viruses.
In this study, we investigated the role of NKG2D in the
expansion of NK cells after mouse CMV (MCMV) in-
fection. Wild-type and NKG2D-deficient (Klrk12/2)
Ly49H+ NK cells proliferated robustly when infected
with MCMV strains engineered to allow expression
of NKG2D ligands, which enhanced the response of
wild-type NK cells. Naive NK cells exclusively express
NKG2D-L, which pairs only with DAP10, whereas
NKG2D-S expressed by activated NK cells pairs with
DAP10 and DAP12, similar to Ly49H. However, NKG2D
alone was unable to drive robust expansion of Ly49H2
NK cells when mice were infected with these MCMV
strains, likely because NKG2D-S was only transiently
expressed postinfection. These findings demonstrate
that NKG2D augments Ly49H-dependent proliferation
of NK cells; however, NKG2D signaling alone is inade-
quate for expansion of NK cells, likely due to only tran-
sient expression of the NKG2D–DAP12 complex. The
Journal of Immunology, 2017, 199: 1567–1571.
N
atural killer cells recognize abnormal or allogeneic
cells by using a variety of receptors that regulate their
activation, cytotoxicity, and cytokine production (1,
2). NK cells have adaptive immune features that include Ag-
specific proliferation after exposure to mouse CMV (MCMV)
and alloantigens (3–6). We have previously demonstrated that
mouse NK cells expressing Ly49H, which specifically recognizes
the m157 MCMV glycoprotein on infected cells (7), robustly ex-
pand after MCMV infection (4). The activating signals through
Ly49H, the costimulatory molecule DNAM-1, and cytokines,
including IL-12, IL-18, and IL-33, are required for the optimal
expansion of effector Ly49H+ NK cells (4, 6, 8–11). Ly49H
associates with the DAP12 and DAP10 adapter molecules to
transmit the activating signaling (12). DAP12-mediated signal-
ing is essential for the clonal expansion of Ag-specific NK cells,
whereas DAP10 augments this response (4, 5, 13).
NKG2D is an activating receptor that is expressed by es-
sentially all NK cells, human CD8+ T cells, mouse activated
CD8+ T cells, gd T cells, subsets of invariant NKT cells, and a
minor population of human CD4+ T cells under certain con-
ditions (14–16). NKG2D recognizes a family of stress-induced
ligands that is distantly related to MHC class I molecules and
is frequently expressed on infected and tumor cells in mice and
humans (16, 17). Human NKG2D, which has no signaling motif
within its short intracellular domain, associates with DAP10
via charged residues in its transmembrane domain (14, 18).
Mouse NKG2D has two isoforms, with a long (NKG2D-L)
or short (NKG2D-S) cytoplasmic domain that is generated
by alternative RNA splicing (19, 20). As in humans, mouse
NKG2D-L associates exclusively with DAP10, whereas mouse
NKG2D-S associates with DAP10 and DAP12 (19, 20). In
mice, naive NK cells exclusively express NKG2D-L. Stimu-
lation of NK cells with IL-2 in vitro or by treatment with
polyinosinic:polycytidylic acid in vivo induces NKG2D-S,
which pairs with DAP12, as demonstrated by the expression
of NKG2D on the cell surface of DAP10-deficient NK cells
after activation (19, 20). NKG2D triggers IFN-g produc-
tion from NK cells and induces NK cell–mediated cyto-
toxicity against target cells expressing its ligands (16, 17,
21–23). However, the role of NKG2D signaling in the ex-
pansion of effector NK cells remains to be elucidated. In this
study, we addressed whether an activating signal through
NKG2D promotes the expansion of NK cells during MCMV
infection.
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Materials and Methods
Mice
C57BL/6 and congenic CD45.1+ C57BL/6 mice were purchased from the
National Cancer Institute and Charles River. NKG2D-deficient (Klrk12/2)
mice (Supplemental Fig. 1), Ly49H-deficient (Klra82/2) mice (24) (gener-
ously provided by Dr. S. Vidal, McGill University), DAP10 (Hcst) and
DAP12 (Tyrobp) double-deficient mice (25) (generously provided by T. Takai,
Tohoku University), DAP10-deficient (Hcst2/2) mice (26), and DAP12-
deficient (Tyrobp2/2) mice (27) on the C57BL/6 background were main-
tained at the University of California, San Francisco in accordance with the
guidelines of the Institutional Animal Care and Use Committee. CD45.1+
wild-type (WT) and CD45.2+ Klrk12/2 mixed bone marrow (BM) chimeric
mice were generated as described (4).
MCMV
Smith strain WT MCMV, Dm151–m158 mutant MCMV (MC96.73) (28),
Dm152 mutant MCMV (29), MCMV expressing RAE-1g (RAE-1g–
MCMV) (30), and MCMV expressing MULT1 (MULT1-MCMV) that was
inserted into the m145 locus were prepared by infecting BALB/c 3T3 cells or
mouse embryonic fibroblasts in cell culture, as described (31). Mice were
infected by i.p. injection of 1–10 3 104 PFU WT or mutant MCMV strains.
In some experiments, Smith strain WT MCMV was prepared by homoge-
nizing salivary glands harvested from infected BALB/c mice, as described (32).
Mice were infected by i.p. injection of 1 3 104 PFU salivary gland WT
MCMV. For in vitro experiments, C57BL/6 3T3 cells were infected with
tissue-cultured MCMV strains at 1 PFU per cell.
NK cell enrichment and adoptive transfer
NK cells were enriched by incubating splenocytes with rat mAbs against mouse
CD4, CD5, CD8, CD19, Gr-1, and Ter119, followed by anti-rat IgG Abs
conjugated to magnetic beads (QIAGEN), as described (8). A total of 200,000
NK cells or 100,000 Ly49H+ NK cells from donor mice was injected i.v. into
recipient mice on the day before infection. In some experiments, Ly49H2 NK
cells were purified using a FACSAria III, and 5 3 104 Ly49H2 NK cells were
injected i.v. into recipient mice on the day before infection. In other experi-
ments, NK cells were cultured in the presence of 1000–2500 U/ml recombi-
nant human IL-2 (generously provided by Prometheus Laboratories) for 3 d.
Flow cytometry
Fc receptors (CD16 and CD32) were blocked with 2.4G2mAb before staining
with the indicated fluorochrome-conjugated mAbs or isotype-matched control
mAbs (BD Biosciences, eBioscience, BioLegend, or TONBOBiosciences). NK
cells were gated as NK1.1+ and TCR b-chain2 lymphocytes. Samples were
acquired on an LSR II or an LSR Fortessa (BD Biosciences), and data were
analyzed with FlowJo software (TreeStar).
Statistical methods
The Student t test or one-way ANOVA was used to compare results. Error
bars represent SEM.
Results and Discussion
NKG2D enhances expansion of Ly49H+ NK cells after
MCMV infection
To determine whether an intrinsic deficiency of NKG2D
affects NK cell responses during MCMV infection, CD45.1+
WT C57BL/6 NK cells and CD45.2+ NKG2D-deficient
(Klrk12/2) C57BL/6 NK cells were adoptively cotransferred
into syngeneic DAP10 and DAP12 double-deficient recipient
mice, which lack functional surface expression of Ly49H and
NKG2D, and were subsequently infected with WT MCMV.
Klrk12/2 Ly49H+ NK cells and WT Ly49H+ NK cells pro-
liferated equivalently after MCMV infection (Fig. 1A). Because
MCMV possesses several proteins that block expression of
NKG2D ligands in infected cells (16, 17), a comparable re-
sponse by WT and NKG2D-deficient NK cells was antici-
pated. To determine whether NKG2D has the potential to
augment an Ly49H+ NK cell response or to directly induce
Ly49H-independent NKG2D-mediated NK cell expansion,
we infected mice with mutant strains of MCMV that were
engineered to permit expression of NKG2D ligands on in-
fected cells. An MCMV mutant strain (Dm152 MCMV)
lacking m152, which downregulates the cell surface expression
of RAE-1 proteins (33, 34), and an MCMV strain engineered
to express the mouse NKG2D ligand RAE-1g (RAE-1g–
MCMV) were used. These mutant MCMV–infected cells
expressed higher amounts of RAE-1 proteins on their surface
compared with cells infected with WT MCMV (Fig. 1B). An
earlier report has demonstrated that viral burdens in mice
infected with the Dm152 MCMV and RAE-1g–MCMV strains
are lower than in mice infected with WTMCMV in an NKG2D-
dependent manner (30). We reconstituted lethally irradiated
recipient mice with CD45.1+ WT and CD45.2+ Klrk12/2 BM
cells and allowed NK cells to reconstitute in the recipient mice
for .5 wk so that WT and NKG2D-deficient NK cells would
develop in the same environment. Ly49H+ NK cells were iso-
lated from the mixed BM chimeric mice, adoptively transferred
into DAP10 and DAP12 double-deficient mice, and infected
with WT MCMV, Dm152 MCMV, or RAE-1g–MCMV.
When infected with RAE-1g–MCMV, WT Ly49H+ NK cells
proliferated more robustly than did Klrk12/2 Ly49H+ NK cells,
with peak NK cell expansion in the blood on day 7 postinfection
(p.i.) (Fig. 1C), although RAE-1g–MCMV is attenuated and
results in reduced viral load when infected in vivo (30). These
results demonstrate that NKG2D is dispensable for MCMV-
specific expansion of Ly49H+ NK cells when infected with the
WT MCMV strain, whereas enhanced NKG2D signaling
amplifies proliferation of Ly49H+ NK cells p.i. with MCMV
strains capable of inducing expression of NKG2D ligands in
the infected cells.
NKG2D signaling alone is insufficient for expansion of NK cells after
MCMV infection
In mice, activated NK cells can express an NKG2D isoform,
NKG2D-S, which pairs and signals throughDAP12 andDAP10,
similar to Ly49H, which also associates with DAP10 and
DAP12 (13) Therefore, we addressed the possibility that
NKG2D signaling through NKG2D-S alone, in the absence of
Ly49H signaling, might support activation and proliferation of
NK cells p.i. with MCMV strains engineered to allow ex-
pression of NKG2D ligands in infected cells. Purified CD45.1+
Ly49H2 WT NK cells and CD45.2+Ly49H2 Klrk12/2 NK
cells were adoptively cotransferred into DAP10 and DAP12
double-deficient recipient mice and then infected with WT
MCMV, RAE-1g–MCMV, or an MCMV strain expressing
the high-affinity mouse NKG2D ligand MULT1 (MULT1-
MCMV). Surprisingly, donor WT Ly49H2 NK cells did not
proliferate robustly in the blood p.i. with WT or mutant MCMV
strains allowing expression of RAE-1g or MULT1 on infected
cells (Fig. 2A). To confirm these results, CD45.1+ Ly49H-
deficient (Klra82/2) NK cells were transferred into DAP10 and
DAP12 double-deficient recipient mice and infected with Dm152
MCMV or RAE-1g–MCMV. These donor Ly49H-deficient NK
cells failed to expand after mutant MCMV infection (Fig. 2B).
These results indicate that NKG2D signaling alone is inadequate
for clonal expansion of NK cells, in contrast to Ly49H.
NK cells downregulate NKG2D by binding with its ligand after
MCMV infection
To investigate the roles of DAP10 and DAP12 in NKG2D
signaling in the absence of Ly49H during MCMV infection,
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we used a mutant MCMV strain Dm151–m158 MCMV,
which lacks the m151–m158 MCMV gene loci. This strain
lacks the m157 ligand of Ly49H, thereby preventing the
immunodominant NK cell response to m157, and deletion
of m152 allows the infected cells to express RAE-1 ligands
(Fig. 3A). WT NK cells, DAP12-deficient (Tyrobp2/2) NK
cells, and DAP10-deficient (Hcst2/2) NK cells were cotrans-
ferred into DAP10 and DAP12 double-deficient mice and
infected with Dm151–m158 MCMV. In infected mice, the
activated WT NK cells would be capable of expressing NKG2D–
DAP12 and NKG2D–DAP10 receptor complexes, Tyrobp2/2
NK cells would exclusively express NKG2D–DAP10 receptor
complexes, and Hcst2/2 NK cells would express only NKG2D–
DAP12 receptor complexes. After infection with Dm151–m158
MCMV, none of the NK cells expanded, and all decreased in
frequency over the course of infection (Fig. 3B), in contrast to the
robust expansion of Ly49H+ NK cells that is observed p.i. with
an MCMV strain expressing m157 (4). Although naive WT and
Tyrobp2/2 NK cells expressed comparable amounts of NKG2D
on their cell surface, consistent with the lack of NKG2D-S
in resting NK cells, naive Hcst2/2 NK cells lacked expression
of NKG2D. After Dm151–m158 MCMV infection, the cell
surface density of NKG2D on WT and Tyrobp2/2 NK cells
decreased significantly, indicating that the NK cells had
likely interacted with NKG2D ligand–bearing cells, which
would cause internalization of NKG2D (35) (Fig. 3C).
Little NKG2D was observed on the cell surface of Hcst2/2
NK cells at all time points during the infection (Fig. 3C).
NK cells only transiently express NKG2D–DAP12 receptor complexes
during MCMV infection
Naive Hcst2/2 NK cells do not express appreciable NKG2D
on their surface (Fig. 4A), whereas naive WT NK cells express
NKG2D. Consistent with prior studies (19, 20), we observed
that in vitro culture of Hcst2/2 NK cells in IL-2 induces
expression of NKG2D–DAP12 receptor complexes on the
FIGURE 1. NKG2D enhances expansion of Ly49H+ NK cells after MCMV infection. (A) A total of 100,000 CD45.1+ WT Ly49H+ NK cells and CD45.2+
NKG2D-deficient Ly49H+ NK cells was cotransferred into DAP10 and DAP12 double-deficient recipient mice and infected with 1 3 105 PFU tissue culture–
propagated WT MCMV. The absolute numbers of donor Ly49H+ NK cells in the blood are shown. Data were pooled from two experiments (n = 7 mice). (B)
Expression of RAE-1 proteins on C57BL/6 3T3 cells at 60 h p.i. with tissue culture–propagated MCMV strains at 1 PFU per cell. Thin and bold lines represent
staining with an isotype-matched control and anti–RAE-1 pan-specific mAb. Data are representative of two experiments. (C) NK cells were purified from
CD45.1+ WT and CD45.2+ Klrk12/2 mixed BM chimeric mice. A total of 100,000 WT and Klrk12/2 Ly49H+ NK cells was transferred into DAP10 and
DAP12 double-deficient mice and infected with 13 105 PFU tissue culture–propagated WTMCMV, Dm152 MCMV, or RAE-1g–MCMV. The kinetics of the
absolute number of donor Ly49H+ NK cells in the blood is represented as the ratio relative to the number of donor Ly49H+ NK cells in the blood on day
0 (before infection). Data are representative of two independent experiments (n = 4 mice per experiment and MCMV strain). *p , 0.05.
FIGURE 2. NKG2D signaling is insufficient for expansion of NK cells after MCMV infection. (A) A total of 53 104 purified CD45.1+Ly49H2WTNK cells
and CD45.2+Ly49H2 Klrk12/2 NK cells was cotransferred into DAP10 and DAP12 double-deficient mice and infected with 1 3 105 PFU tissue culture–
propagated WT MCMV, RAE-1g–MCMV, or MULT1-MCMV. Donor NK cells were identified by expression of CD45 congenic markers. The kinetics of the
absolute number of donor Ly49H2 NK cells in the blood is represented as the ratio relative to the number of donor Ly49H2 NK cells in the blood on day
0 (before infection). Data are representative of two independent experiments (n = 3 mice per experiment and MCMV strain). (B) A total of 200,000 CD45.1+
Ly49H-deficient NK cells was transferred into DAP10 and DAP12 double-deficient mice and infected with 1 3 104 PFU tissue culture–propagated Dm152
MCMV or RAE-1g–MCMV. The kinetics of the absolute number of donor NK cells in the blood is represented as the ratio relative to the number of donor NK
cells in the blood on day 0 (before infection). Data are representative of two independent experiments (n = 3 mice per experiment and MCMV strain).
The Journal of Immunology 1569
 by guest on O
ctober 30, 2018
http://w
w
w
.jimmunol.org/
D
ow
nloaded from
 
cell surface (Fig. 4B). Although we did not detect expression
of NKG2D on the cell surface of Hcst2/2 NK cells p.i. with
Dm151–m158 MCMV, it is possible that NKG2D-S was
induced during the infection but that the NKG2D–DAP12
receptor complex was downmodulated by interaction with
RAE-1 on the infected cells because, in the absence of m152,
RAE-1 is expressed on the surface of infected cells. Therefore,
to determine whether NKG2D–DAP12 complexes are expressed
on NK cells after MCMV infection, WT and Hcst2/2mice were
infected with WT MCMV, because WT MCMV efficiently
blocks the expression of NKG2D ligands on infected
cells, therefore avoiding ligand-induced downmodulation of
NKG2D. Hcst2/2 Ly49H+ NK cells indeed expressed low
amounts of DAP12-associated NKG2D on day 2 p.i.; however,
this was transient, and no NKG2D was detected on Ly49H+ NK
cells by day 14 (Fig. 4C). These findings imply that NKG2D–
DAP12 complexes are only transiently expressed during in-
fection and, once induced, expression apparently is not stable.
A previous study demonstrated that the deficiency of
NKG2D causes faster homeostatic cell division of NK cells and
augments their sensitivity to apoptosis in the naive state (36).
Although Klrk12/2 NK cells were reported to exhibit a faster
maturation and enhanced IFN-g production when infected
with an MCMV strain lacking m157 (36), our results dem-
onstrate that expansion of MCMV-specific Ly49H+ NK cells
lacking NKG2D is intact when infected with WT MCMV.
The activating Ly49H and Ly49D receptors associate with
DAP12 and DAP10, and both receptors are capable of driving
NK cell expansion when stimulated by their cognate ligands,
MCMV m157 (4, 6) and H-2Dd alloantigens (5), respectively.
Because NKG2D can also pair with DAP10 and DAP12, this
prompted us to determine whether activation through NKG2D
could also drive clonal expansion of NK cells. Because NKG2D
ligands are express by many tumors and by cells infected with
numerous pathogens (37), if NKG2D receptor signaling were
capable of driving NK cell expansion, this would be beneficial in
host defense and provide a therapeutic opportunity for cancer.
However, in contrast to Ly49H, NKG2D alone is unable to
promote robust expansion of NK cells during MCMV infection,
even when the MCMV genes that prevent RAE-1 expression in
infected cells are removed from the viral genome or in MCMV
strains that are engineered to overexpress mouse NKG2D
ligands in infected cells. We also failed to induce NKG2D-
dependent NK cell expansion when mice were challenged with
NKG2D ligand–bearing tumors in the context of a viral in-
fection to provide proinflammatory cytokines to augment the
response (T. Nabekura, K. Niizuma, and L.L. Lanier, unpub-
lished observations). In the case of Ly49H, Ly49H–DAP12 re-
ceptor complexes are essential to drive extensive proliferation
during MCMV infection (4, 38). Although Ly49H–DAP10
receptors can be detected in low amounts on the surface of
Tyrobp2/2 NK cells, NK cells lacking DAP12 had a signifi-
cantly impaired proliferative response after MCMV infection
compared with WT NK cells (13). The inability of NKG2D–
DAP12 receptors to induce a robust expansion is likely due to
the transient expression of NKG2D–DAP12 complexes during
MCMV infection. These findings support the concept that the
strength of DAP10 signaling modulates the magnitude of
FIGURE 3. NK cells downregulate NKG2D after MCMV infection. (A) Expression of RAE-1 proteins on C57BL/6 3T3 cells at 60 h p.i. with tissue culture–
propagated Dm151–m158 MCMV at 1 PFU per cell. Thin and bold lines represent staining with an isotype-matched control and anti–RAE-1 pan-specific mAb.
Data are representative of two experiments. (B and C) A total of 200,000 CD45.1+CD45.2+ WT NK cells, CD45.1+ Tyrobp2/2 NK cells, and CD45.2+ Hcst2/2
NK cells was cotransferred into DAP10 and DAP12 double-deficient mice and infected with 1 3 105 PFU tissue culture–propagated Dm151–m158 MCMV.
Donor WT NK cells and Tyrobp2/2 NK cells were identified by expression of CD45 congenic markers, and donor Hcst2/2 NK cells were identified by expression
of Ly49H and CD45 congenic markers. (B) The kinetics of the absolute number of donor NK cells in the blood is represented as the ratio relative to the number
of donor NK cells in the blood on day 0 (before infection). (C) Expression of NKG2D on donor NK cells in the blood is represented as mean fluorescent intensity
(MFI). Data were pooled from two experiments (n = 8 mice). *p , 0.05 versus WT.
FIGURE 4. NK cells only transiently express DAP12-associated NKG2D after MCMV infection. (A and B) WT, Hcst2/2, and DAP10 and DAP12 double-
deficient NK cells were stained with control Ig or anti-NKG2D mAb. (A) Expression of NKG2D on naive WT NK cells (thin line), Hcst2/2 NK cells (bold line),
and DAP10 and DAP12 double-deficient NK cells (filled graph) is shown. (B) WT, Hcst2/2, and DAP10 and DAP12 double-deficient NK cells were cultured in
the presence of 1000 U/ml human IL-2 for 3 d. Expression of NKG2D on IL-2–cultured WT NK cells (thin line), Hcst2/2 NK cells (bold line), and DAP10 and
DAP12 double-deficient NK cells (filled graph) is shown. (C) WT and Hcst2/2 mice were infected with 1 3 104 PFU in vivo salivary gland–passaged WT
MCMV. Expression of NKG2D on Ly49H+ NK cells in the blood is represented as mean fluorescent intensity (MFI). Data were pooled from two experiments
(n = 2–10 mice). *p , 0.05 versus day 0.
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expansion of NK cells, whereas DAP12 is the essential driver
for expansion of Ag-specific NK cells. The action of DAP10
in NK cells is reminiscent of costimulatory signals for TCRs
in T cells. In accordance with this, previous studies have
reported that NKG2D acts as a costimulatory receptor on
CD8+ T cells (39–42). Reciprocally, DAP12 serves as the
dominant driver of activation by its recruitment of Syk and
ZAP-70 tyrosine kinases, which are also responsible for
downstream signal transduction of the CD3 subunits of the
TCR (43–45). Conceptually, DAP12 signaling through activat-
ing Ly49 receptors on NK cells is functionally analogous to TCR
signaling in T cells, with DAP10 functioning in a costimulatory
role. Intriguingly, mice immunized with an MCMV strain
engineered to express a mouse NKG2D ligand exhibit an ampli-
fied CD8+ T cell response and improved survival against the
secondary challenge with virulent MCMV compared with
mice initially immunized with WT MCMV (30). Similarly,
our current study revealed an enhanced Ly49H+ NK cell re-
sponse in mice infected with the MCMV strain expressing
mouse NKG2D ligands, suggesting a new strategy to possibly
augment NK cell responses in the context of vaccination.
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